Thus, it is tempting to speculate that targeting lipid metabolism, for instance utilizing a PPAR-α agonist which specifically targeted T cells in the TME (53), to promote fatty acid catabolism by CD8+ T cells, or blocking the activated fatty acid metabolism pathway of cancer cells, may be a potential therapeutic option. The gene discussed is CD8A; the disease is cancer.